Transcatheter aortic valve implantation (TAVI) has become the new standard of care for inoperable patients with symptomatic aortic stenosis and an alternative for selected high-risk operable patients.
What is the current evidence and clinical implications of transcatheter aortic valve implantation (TAVI) compared to surgical aortic valve replacement (SAVR) in patients with severe symptomatic aortic stenosis?
This 10-year anniversary review summarizes the evolution of TAVI into the standard of care for inoperable patients and a viable alternative for high-risk operable patients with severe symptomatic aortic stenosis.
Surgical aortic valve replacement (SAVR) is currently the standard of care to treat patients with severe symptomatic aortic stenosis (AS) and is generally accepted to alleviate symptoms and prolong survival. Based on the results of randomized trials, transcatheter aortic valve implantation (TAVI) is the new standard of care for patients with symptomatic AS who are deemed 'inoperable'. Debatably, TAVI is also an alternative to SAVR in selected patients who are at high risk but operable. As we approach 10 years of clinical experience with TAVI, with over 50 000 implantations in 40 countries, a review of the current literature and clinical outcomes with this rapidly evolving technology is appropriate.
Généreux et al. (2012) conducted a review in Severe symptomatic aortic stenosis. Transcatheter aortic valve implantation (TAVI) vs. Surgical aortic valve replacement (SAVR) was evaluated. Transcatheter aortic valve implantation (TAVI) has become the new standard of care for inoperable patients with symptomatic aortic stenosis and an alternative for selected high-risk operable patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: